1. Home
  2. JELD vs NERV Comparison

JELD vs NERV Comparison

Compare JELD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.39

Market Cap

152.7M

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$2.38

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
NERV
Founded
1960
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.7M
166.4M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
JELD
NERV
Price
$1.39
$2.38
Analyst Decision
Hold
Buy
Analyst Count
3
3
Target Price
$1.93
★ $10.33
AVG Volume (30 Days)
★ 1.6M
135.5K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $3,211,181,000.00
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.28
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.93
$2.31
52 Week High
$4.92
$12.46

Technical Indicators

Market Signals
Indicator
JELD
NERV
Relative Strength Index (RSI) 36.69 22.50
Support Level $1.31 N/A
Resistance Level $2.18 $5.69
Average True Range (ATR) 0.17 0.25
MACD -0.05 -0.07
Stochastic Oscillator 14.90 6.25

Price Performance

Historical Comparison
JELD
NERV

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: